ライフサイエンスコーパス: hemoglobin A1c

1 l MFN1 content was inversely proportional to hemoglobin A1C.

2 oprotein cholesterol, smoking cessation, and hemoglobin A1c.

3 timated insulin resistance, and glycosylated hemoglobin A1c.

4 ore and liver stiffness) and correlated with hemoglobin A1C.

5 biopsies of patients with diabetes mellitus (hemoglobin A1c, 10+/-2%) demonstrated reduced overall ce

6 from 40 patients (mean age, 58 yr [SD, 10], hemoglobin A1c 36.8 mmol/mol [4.9 mmol/mol]) with 35 att

7 al cholesterol (194 vs 186 mg/dL; P = .027), hemoglobin A1c (5.9% vs 5.7%; P = .003), and body mass i

8 A1c=6.5 +/- 0.15), and nondiabetic patients (hemoglobin A1c=5.4 +/- 0.12) undergoing coronary artery

9 0.25), controlled type 2 diabetic patients (hemoglobin A1c=6.5 +/- 0.15), and nondiabetic patients (

10 erular filtration rate, mL/min per 1.73m(2); hemoglobin A1c, 8.0%; 62.9% men; diabetes mellitus durat

11 en patients with poorly controlled PDR (mean hemoglobin A1C = 9.2 +/- 2.0%) and 10 control subjects w

12 from uncontrolled type 2 diabetic patients (hemoglobin A1c=9.6 +/- 0.25), controlled type 2 diabetic

13 d as a health care provider diagnosis, serum hemoglobin A1C (A1C) >/=6.5%, or fasting plasma glucose

14 The importance of glycosylated hemoglobin A1c (A1c) control as part of comprehensive ri

15 t each visit for the assay of serum glycated hemoglobin A1c (A1c), hsCRP, d-8-iso, MMP-2, and MMP-9.

16 essure, low-density lipoprotein cholesterol, hemoglobin A1c, albuminuria, glomerular filtration rate,

17 Lower hemoglobin A1c and BP and regression to AER<300 mg/d wer

18 amples were used to assess concentrations of hemoglobin A1c and C-reactive protein.

19 etabolic profiling, including measurement of hemoglobin A1c and lipid levels and carotid ultrasonogra

20 medical evaluation and management services, hemoglobin A1C and lipid testing (n = 1,489 persons with

21 A total of 15,737 patients had an hemoglobin A1c and medical record evaluable for the hist

22 type, NAS >/= 5, bilirubin, body mass index, hemoglobin A1C, and dyslipidemia.

23 mass index, diabetes duration, glycosylated hemoglobin A1c, and fasting C-peptide.

24 l assessment of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had sig

25 l assessment of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had sig

26 ence definitions defined by fasting glucose, hemoglobin A1c, and medication use obtained during an in

27 The effect of lorcaserin on weight, hemoglobin A1c, and systolic blood pressure was consiste

28 anic blacks, individuals with high levels of hemoglobin A1c, and those with longer duration of diabet

29 ace, follow-up interval, insulin dependence, hemoglobin A1c, and total number of lasers spots.

30 nificantly greater weight loss, reduction in hemoglobin A1c, and use of antidiabetic medications, and

31 liter), C-peptide (in nanomoles per liter), hemoglobin A1c (as a percentage) and insulin dose (U/kg

32 nfidence interval [CI], 0.38-0.44; P<0.001), hemoglobin A1C assessment (odds ratios 0.41; 95% CI, 0.3

33 (odds ratio [OR], 0.77 [95% CI, 0.65-0.91]); hemoglobin A1c assessment (OR, 0.79 [95% CI, 0.66-0.94])

34 Measurement of hemoglobin A1c at admission can prospectively identify a

35 Prediabetes (glucose based, 4.0%; hemoglobin A1c based, 15.4%) and diabetes (glucose based

36 d, 15.4%) and diabetes (glucose based, 3.0%; hemoglobin A1c based, 2.9%) were less frequent.

37 , 65.5%, 56.6%, and 80.6% met individualized hemoglobin A1c, blood pressure (BP <140/80 mmHg), lipid

38 ciation was independent of diabetes control (hemoglobin A1c, blood pressure, and lipid levels), prese

39 Plasma lipids, hemoglobin A1C, body composition, the oral glucose toler

40 goals, respectively; 26.7% met combined ABC (hemoglobin A1c, BP, and LDL cholesterol) targets, and 21

41 d adults, 77.0%, 57.9%, 36.0%, and 77.9% met hemoglobin A1c, BP, lipid, and nonsmoking goals, respect

42 w prehospital admission levels (estimated by hemoglobin A1C) but not to absolute hypoglycemia levels.

43 Tested as continuous variables, glycated hemoglobin A1C, but neither body mass index nor the insu

44 se by 0.69 mmol/L [1.32; 0.07], glycosylated hemoglobin A1C by 0.37% [0.54; 0.20], body weight by 2.5

45 disease, alcohol/drug use, income/education, hemoglobin A1C, C-reactive protein, lactate dehydrogenas

46 h or without metformin had similar levels of hemoglobin A1c, cholesterol, and blood pressure.

47 i-diabetic medications, as well as levels of hemoglobin A1C, cholesterol, hemoglobin, creatinine, and

48 model assessment of insulin resistance, and hemoglobin A1c) compared with fast ethanol metabolizers

49 random glucose level of at least 200 mg/dL, hemoglobin A1c concentration of at least 6.5% of total h

50 gainst statistically significant declines in hemoglobin A1c control.

51 age, race, gender, laterality, insulin use, hemoglobin A1c, creatinine, blood urea nitrogen, and est

52 hemoglobin A1c (P <= 0.001) among those with hemoglobin A1c data.

53 h empagliflozin, even though, by design, the hemoglobin A1c difference between the randomized groups

54 ntrolled for age, gender, race or ethnicity, hemoglobin A1c, duration of diabetes, high-density lipop

55 Blood samples were assessed for hemoglobin A1c, fasting blood glucose, and serum lipids.

56 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin were abstra

57 BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and li

58 ission of type 2 diabetes, hypertension, and hemoglobin A1c, fasting insulin, homeostatic model asses

59 Mean hemoglobin A1c for the population was 7.9+/-1.8%.

60 ized prevalence of total diabetes (using the hemoglobin A1c, FPG, or 2-hour PG definition) was higher

61 e (2-hour PG) level of 200 mg/dL or greater (hemoglobin A1c, FPG, or 2-hour PG definition).

62 lation, the unadjusted prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabet

63 sex, race/ethnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

64 ted compounds to detect tHb and glycosylated hemoglobin A1c (GHbA1c) in human whole blood without sam

65 The percentage of glycosylated hemoglobin A1c (%GHbA1c) in human whole blood indicates

66 but nonsignificant effects on the change in hemoglobin A1c, glucose, and insulin levels.

67 We measured plasma levels of hemoglobin A1c, glucose, insulin, glucagon, adipocytokin

68 Hemoglobin A1c goals are less than 6.5% at conception an

69 Insulin can help achieve ideal hemoglobin A1c goals for patients with type 2 diabetes.

70 Diabetes was defined as hemoglobin A1c greater than 6.5% or use of glucose-lower

71 Among patients with hemoglobin A1c greater than or equal to 8.0% treated in

72 emia increased; however, among patients with hemoglobin A1c greater than or equal to 8.0%, the opposi

73 n 6.5% and 6.5-7.9% but not among those with hemoglobin A1c greater than or equal to 8.0%.

74 This represented 41.0% of patients with an hemoglobin A1c > 6.5% and 9.3% of all ICU patients.

75 diabetes), and uncontrolled known diabetes (hemoglobin A1c > 6.5%, with documented history of diabet

76 were categorized as having unknown diabetes (hemoglobin A1c > 6.5%, without history of diabetes), no

77 00/140/200 mg/dL [5.55/7.77/11.10 mmol/L] or hemoglobin A1C >/= 5.7% [39 mmol/mol]); (2) diagnosis co

78 herapy for >/= 30 consecutive days, and (iv) hemoglobin A1c >/= 6.5%.

79 the use of DM medication, a DM diagnosis, or hemoglobin A1c >= 6.5%.

80 We defined diabetes as hemoglobin A1c >=6.5% or self-report and CKD by urinary

81 g glucose (>/=7.0 mmol/L [>/=126 mg/dL]) and hemoglobin A1c (>/=6.5%) in persons without diagnosed di

82 ferritin, adiponectin, fasting insulin, and hemoglobin A1c (Hb A1c).

83 amperometric method for direct detection of hemoglobin A1c (Hb(A1c)), a potent biomarker for diabete

84 entral adiposity, stable adiposity, baseline hemoglobin A1c (HbA1c) > 5.05%, HbA1c < 4.92%] and assay

85 glucose >/=200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported physician-di

86 n excretion rate, and DCCT/EDIC mean updated hemoglobin A1c (HbA1c) (2-step progression: HR, 1.28; 95

87 Hemoglobin A1c (HbA1c) and fasting blood glucose levels

88 ay for the dual detection and measurement of hemoglobin A1c (HbA1c) and total hemoglobin in the whole

89 ve of this study is to evaluate the value of hemoglobin A1c (HbA1c) as a screening tool for ketosis i

90 The association of baseline hemoglobin A1c (HbA1c) at the time of percutaneous coron

91 mellitus (T2DM) may fail to achieve adequate hemoglobin A1c (HbA1c) control despite metformin-sulfony

92 icular blood (GCB) could be used to test for hemoglobin A1c (HbA1c) during periodontal visits.

93 Primary outcome was change in hemoglobin A1c (HbA1c) from baseline to 12-month follow-

94 The primary end point was change in hemoglobin A1c (HbA1c) from baseline to week 26.

95 -14)) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of Europea

96 Hemoglobin A1C (HbA1C) is associated with increased risk

97 We investigated whether elevated hemoglobin A1c (HbA1c) is associated with the developmen

98 Hemoglobin A1c (HbA1c) is the standard measure to monito

99 Hemoglobin A1c (HbA1c) is widely used to diagnose diabet

100 nce interval [CI], 1.7%-3.3% per 5 kg/m(2)), hemoglobin A1c (HbA1c) level (2.2%; 95% CI, 1.0%-3.5% pe

101 - standard deviation was 14.0 +/- 1.5 years, hemoglobin A1C (HbA1C) level was 8.5 +/- 1.3%, and media

102 verse events, myocardial infarction, stroke, hemoglobin A1c (HbA1C) level, treatment failure (rescue

103 revalence and control of diabetes defined by hemoglobin A1c (HbA1c) levels are important for health c

104 Hemoglobin A1c (HbA1c) levels are known to be consistent

105 Hemoglobin A1C (HbA1c) levels are often obtained in pote

106 tudy was to investigate whether preoperative hemoglobin A1c (HbA1c) levels could predict cardiovascul

107 The primary outcome was the change in mean hemoglobin A1c (HbA1c) levels estimated over three 12-mo

108 asma insulin levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in first-episode antipsych

109 Debate exists as to whether the higher hemoglobin A1c (HbA1c) levels observed in black persons

110 and poorly controlled blood glucose levels (hemoglobin A1c (HbA1c) levels of >7) also had intracellu

111 ls of 12.5 mmol/L or less (</=225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% who were t

112 ultiple daily injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5

113 ng multiple daily insulin injections and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%.

114 Hemoglobin A1c (HbA1c) levels were also recorded.

115 tion was collected using a questionnaire and hemoglobin A1c (HbA1c) levels were measured.

116 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels were recorded.

117 Hemoglobin A1c (HbA1c) levels were recorded.

118 or gender, diabetes type, diabetes duration, hemoglobin A1c (HbA1c) levels, and baseline DR severity.

119 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels, periodontal parameters (p

120 hour glucose level of 200 mg/dL or higher, a hemoglobin A1c (HbA1c) of 6.5% or higher, or diabetes tr

121 24 years with type 1 diabetes and screening hemoglobin A1c (HbA1c) of 7.5% to 10.9%.

122 5.2 years (range, 0.1-16.2 years) and a mean hemoglobin A1c (HbA1c) of 8.6 (range, 5->/=14).

123 ded 161 individuals with type 1 diabetes and hemoglobin A1c (HbA1c) of at least 7.5% (58 mmol/mol) tr

124 re-9 score of at least 10 (range, 0-27); and hemoglobin A1c (HbA1c) of at least 8%, systolic blood pr

125 e the effect of glycemic status evaluated by hemoglobin A1c (HbA1c) on the risk of thromboembolism am

126 Whether preoperative hemoglobin A1c (HbA1c) or postoperative glucose levels a

127 Measurement of hemoglobin A1c (HbA1c) provides an estimate of mean bloo

128 Hemoglobin A1c (HbA1c) reflects past glucose concentrati

129 r than 65 years, the harms associated with a hemoglobin A1c (HbA1c) target lower than 7.5% or higher

130 ls of fasting plasma glucose (FPG) and blood hemoglobin A1c (HbA1c) than individuals of other genotyp

131 Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent coronary hear

132 tic nephropathy group and patients with high hemoglobin A1c (HbA1c) values (>/= 6.5%, >/= 48 mmol/mol

133 ssociation between baseline and time-varying hemoglobin A1c (HbA1c) values and development of communi

134 ams divided by height in meters squared) and hemoglobin A1c (HbA1c) was greater than or equal to 6.5%

135 oprotein [HDL], and triglycerides [TGs]) and hemoglobin A1C (HbA1C) were measured during treatment, w

136 on between duration of diabetes and elevated hemoglobin A1c (HbA1c) with risk of stroke among diabeti

137 DL and HDL cholesterol, triglycerides (TGs), hemoglobin A1c (HbA1c), and homeostasis model assessment

138 ne at week 100 by age, duration of diabetes, hemoglobin A1c (HbA1c), body mass index (BMI), best-corr

139 ng-term pharmacodynamic effects, assessed by hemoglobin A1c (HbA1c), body weight, and blood lipid con

140 etes during the interview or measurements of hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), an

141 intervals (CIs) were calculated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), to

142 arkers [blood pressure, waist circumference, hemoglobin A1c (HbA1c), insulin resistance, triglyceride

143 Pioglitazone treatment improved hemoglobin A1c (HbA1c), plasma glucose, insulin levels,

144 a meta-analysis for the glycemic outcome of hemoglobin A1c (HbA1c).

145 s) may be associated with acute decreases in hemoglobin A1c (HbA1c).

146 g levels of glucose, insulin, proinsulin and hemoglobin A1c (HbA1c).

147 th respect to age, sex, body mass index, and hemoglobin A1C (HbA1C).

148 st circumference, lipids, serum glucose, and hemoglobin A1c (HbA1c).

149 Unfortunately, tests such as hemoglobin A1c (HbA1c)/fasting plasma glucose (FPG) alon

150 lycemia, hyperglycemia, and glucose control; hemoglobin A1c (HbA1c); and cognition and patient-report

151 rt a potentiometric method for measuring the hemoglobin A1c (HbA1c, glycated hemoglobin) concentratio

152 ith suboptimally controlled type 1 diabetes (hemoglobin A1c [HbA1c] >8.0%) were recruited from the Di

153 %) had diabetes, 1268 (34%) had prediabetes (hemoglobin A1c [HbA1c] 5.7-6.4%), and 606 (16%) had norm

154 cantly correlated with DM-related variables (hemoglobin A1c [HbA1c] and fasting glucose) at baseline

155 level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases w

156 hese risks vary with glycated hemoglobin (or hemoglobin A1c [HbA1c]) levels is unclear.

157 Clinical characteristics, glycemic control (hemoglobin A1c [HbA1c]), and presence of diabetic compli

158 s in glycemic control (>/= 0.4% reduction in hemoglobin A1c [HbA1c]), whereas most diabetes self-mana

159 betes mellitus and glycemic status (baseline hemoglobin A1c [HbA1c]: < 6.0% [< 42 mmol/mol], 6.0%-6.4

160 before and after CPB from the UDM patients (hemoglobin A1c [HbA1c]=9.0 +/- 0.3), the CDM patients (H

161 index, high-sensitivity C-reactive protein, hemoglobin A1c, HDL cholesterol, LDL cholesterol, and tr

162 hieved stable glycemic control with a median hemoglobin A1C (HgA1C) of 6.9% (range: 5.85%-8.3%).

163 Fasting serum glucose, insulin, and hemoglobin A1C (HgbA1C) were measured; insulin resistanc

164 cted data on histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, smoking, a

165 A second example concerns changes in hemoglobin A1c in a nonrandomized study.

166 correlation between FA of the left ALIC with hemoglobin A1c in diabetic subjects (DC+DD; P=.016).

167 riodontal treatment is associated with lower hemoglobin A1c in individuals with diabetes, but the rel

168 sed by either medical history or an elevated hemoglobin A1c in the ICU.

169 Mean hemoglobin A1c increased from baseline during the study:

170 ocalcin, osteopontin, and serum glycosylated hemoglobin A1c, insulin, and glucose were analyzed in 22

171 mic capillary isoelectric focusing separated hemoglobin A1c into two subfractions identified as A1c1

172 ed with higher mortality among patients with hemoglobin A1c less than 6.5% (p < 0.0001 for each).

173 ed with higher mortality among patients with hemoglobin A1c less than 6.5% and 6.5-7.9% but not among

174 Among patients with hemoglobin A1c less than 6.5%, mortality increased as me

175 ncreasing mortality only among patients with hemoglobin A1c less than 6.5%.

176 140 mg/dL or 110-160 mg/dL for patients with hemoglobin A1c less than 7% or greater than or equal to

177 Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood glucose

178 Patients were stratified by hemoglobin A1c: less than 6.5.(n = 4,406), 6.5-7.9% (n =

179 Eight participants developed diabetes (hemoglobin A1c level >/=6.5%) during the trial: 7 in the

180 ure level >90 mm Hg), uncontrolled diabetes (hemoglobin A1c level >8%), obesity (body mass index >30)

181 that intensified risk factor control in YOD (hemoglobin A1c level <6.2%, systolic blood pressure <120

182 vel (-20.2 mg/dL; 95% CI=-39.2 to -1.3), and hemoglobin A1c level (-0.07%; 95% CI=-0.14 to -0.004).

183 They had a favorable effect on hemoglobin A1c level (mean difference vs. placebo, -0.66

184 Change in hemoglobin A1c level (primary outcome) and safety and ef

185 ith interstitial macrophage infiltration and hemoglobin A1c level and inversely with estimated glomer

186 th T2DM-related clinical measures, including hemoglobin A1c level and vascular risk factors, and neur

187 In a meta-analysis, hemoglobin A1c level decreased by 0.4% (95% CI, 0.1% to

188 Diabetes was defined as hemoglobin A1c level of >/=6.5%, use of diabetic medicat

189 ucose level of 410 mg/dL (22.8 mmol/L) and a hemoglobin A1C level of 18.0%.

190 Prediabetes was defined as a hemoglobin A1c level of 5.7% to 6.4%, an FPG level of 10

191 betes was not previously diagnosed, by (1) a hemoglobin A1c level of 6.5% or greater or a fasting pla

192 of 55.8 mL/min/1.73 m2 [IQR, 51.6-58.2] and hemoglobin A1c level of 6.6% [IQR, 6.1%-7.2%] at cohort

193 Participants with a hemoglobin A1c level of 7% or greater, diabetes, or othe

194 nd 18.5% had type 1 diabetes and a mean (SD) hemoglobin A1C level of 7.7% (1.8) (n = 27).

195 The mean (SD) hemoglobin A1c level was 7.8% (2.4%) (to convert to prop

196 n for a median of 14 months (IQR, 5-30), and hemoglobin A1c level was 8.1% (IQR, 7.2%-9.9%).

197 55 years, 48% were female, average baseline hemoglobin A1c level was 8.7%, and 27% were prescribed i

198 Hemoglobin A1c level was not associated with any MR imag

199 Current hemoglobin A1c level was not associated with either rece

200 py, accompanied with a subsequently recorded hemoglobin A1c level<6.0%).

201 Mean (SD) age was 47.3 (6.4) years and hemoglobin A1c level, 7.9% (2.0%).

202 t, 47.3 (6.6) years for age, 7.8% (1.9%) for hemoglobin A1c level, and 171.3 (72.5) mg/dL for fasting

203 adjusting for duration of diabetes, glycated hemoglobin A1c level, and other factors, we found that n

204 After adjustment for sex, age, hemoglobin A1c level, and retinopathy level at DCCT base

205 ore (ie, blood pressure, waist to hip ratio, hemoglobin A1c level, and the ratio of apolipoprotein B

206 ype 2 diabetes and established risk factors (hemoglobin A1c level, body mass index, waist-height rati

207 emographics, medications, cholesterol level, hemoglobin A1c level, creatinine level, blood pressure,

208 ristics analyzed included age, gender, race, hemoglobin A1C level, hypertension, systolic blood press

209 evelopment of any DR were diabetes duration, hemoglobin A1C level, insulin use, and end-organ damage.

210 , body mass index, C-reactive protein level, hemoglobin A1c level, phosphorus level, troponin T level

211 Baseline descriptive data, hemoglobin A1c (%) level, time since diagnosis of T1DM (

212 in (numeric rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, body mass i

213 +/- 14 mg/dL vs 8 +/- 17 mg/dL [P < .001]), hemoglobin A1c levels (26 weeks: 0.1 +/- 0.3% vs 0.3 +/-

214 ntation resulted in a remarkable decrease in hemoglobin A1c levels (7.4+/-1.9 pre-LVAD versus 6.0+/-1

215 tion was associated with significantly lower hemoglobin A1c levels (beta = -0.37; 95% CI, -0.72 to -0

216 amcinolone group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%;

217 Patients with higher hemoglobin A1c levels (OR, 1.19 per unit change; 95% CI,

218 Lower hemoglobin A1c levels (P < 0.01), having insurance (P =

219 d oral glucose tolerance (P < 0.01), reduced hemoglobin A1c levels (P = 0.01), and improved insulin s

220 -stratified blood pressure, cholesterol, and hemoglobin A1c levels and treatment and control rates in

221 Although mean hemoglobin A1c levels between groups were equivalent, th

222 bjects with high depression ratings and high hemoglobin A1c levels had the lowest mean FA values in t

223 Glycated hemoglobin A1c levels improved to 7.0% [6.4%-7.5%] in th

224 ly correlated with fasting blood glucose and hemoglobin A1c levels in men with T2DM, but not women wi

225 tage of participants with diabetes achieving hemoglobin A1c levels less than 6.5% or fasting plasma g

226 s index and triglyceride, blood glucose, and hemoglobin A1c levels sharply decreased during the first

227 Increasing hemoglobin A1c levels were associated with significant i

228 ata were collected using a questionnaire and hemoglobin A1c levels were measured.

229 Hemoglobin A1c levels were ordered at all ICU admissions

230 ntrol (range, 0.9-1.43 point improvements in hemoglobin A1c levels) during 1 to 2 years of follow-up

231 ssure), measures of diabetes status (such as hemoglobin A1c levels), and quality of life.

232 k factors for CVD, inflammatory markers, and hemoglobin A1c levels).

233 Such patients had higher glycemic lability, hemoglobin A1C levels, and Acute Physiology and Chronic

234 ed by testing fasting plasma glucose levels, hemoglobin A1c levels, and duration of diabetes.

235 ypoglycemia is common, increases with higher hemoglobin A1C levels, and is a modifiable risk factor f

236 lucose levels, oral glucose tolerance tests, hemoglobin A1C levels, and/or antidiabetic medications.

237 ical variables, including age, gender, race, hemoglobin A1C levels, blood pressure, cholesterol level

238 o short-term effect on secondary outcomes of hemoglobin A1c levels, depression, or the Risk Perceptio

239 dults, undiagnosed adults have less elevated hemoglobin A1c levels, less lipid treatment and worse co

240 Vision Function Questionnaire 25 scores and hemoglobin A1c levels.

241 (with the exception of interleukin 22) with hemoglobin A1c levels.

242 determined by assessment of HbA1c (glycated hemoglobin A1c) levels, which poorly reflects direct glu

243 ory of diabetes), controlled known diabetes (hemoglobin A1c < 6.5%, with documented history of diabet

244 , without history of diabetes), no diabetes (hemoglobin A1c < 6.5%, without history of diabetes), con

245 ts of intensive and standard treatment were: hemoglobin A1c <6.0% and 7.0% to 7.9%, respectively, and

246 Rate of remission of T2DM (hemoglobin A1C <6.0% without antiglycemic medication) wa

247 likely to achieve diabetes mellitus control (hemoglobin A1c <=7% in 51.3% versus 54.3%; P<0.001 for a

248 of 4 measures-blood pressure <140/90 mm Hg, hemoglobin A1c <=9% in diabetic patients, statin use, an

249 litus and prediabetes was estimated based on hemoglobin A1c measurements.

250 Preadmission glycemia, reflected by hemoglobin A1c obtained at the onset of ICU admission, h

251 countries among adults with type 2 diabetes, hemoglobin A1c of 6.5% to 10.0%, high CV risk (history o

252 to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.

253 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 24 women;

254 density or foveal avascular zone metrics and hemoglobin A1C or duration of diabetes.

255 ized prevalence of total diabetes (using the hemoglobin A1c or FPG definition) increased from 9.8% (9

256 glucose (FPG) level of 126 mg/dL or greater (hemoglobin A1c or FPG definition) or (2) additionally in

257 sted prevalence of total diabetes (using the hemoglobin A1c or FPG definition) was 12.3% (95% CI, 10.

258 0.7-1.7), was 40% higher per 1% increase in hemoglobin A1c (OR = 1.4, 95% CI 1.1-1.6), was 30% highe

259 95% CI, 1.07-1.11 per year increase), higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34 per percent

260 Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71 for each 1%;

261 iated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?

262 ciation between the continuous DNN score and hemoglobin A1c (P <= 0.001) among those with hemoglobin

263 ncreasing level of alanine aminotransferase, hemoglobin A1C (P<.05), gamma-glutamyl transferase and d

264 f baseline waist circumference with glycated hemoglobin A1c reduction is likely due to selection bias

265 The only significant predictor of glycated hemoglobin A1c reduction was waist circumference, lower

266 Empagliflozin reduced hemoglobin A1c significantly in both groups, despite low

267 duration of diabetes mellitus, glycosylated hemoglobin A1c, statin use, and end-stage renal disease.

268 Hemoglobin A1c stratified by the presence or absence of

269 ively and significantly associated with BMI, hemoglobin A1c, systolic blood pressure, total cholester

270 The hemoglobin A1c target for most patients with type 2 diab

271 shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment p

272 xamination (OR = 1.49; CI, 1.28-1.74), prior hemoglobin A1c test (OR = 1.45; CI, 1.28-1.64), and havi

273 of incident cases had a glycated hemoglobin (hemoglobin A1c) test as one of the pair of events identi

274 12 months after ICU admission and underwent hemoglobin A1c testing and an oral glucose tolerance tes

275 ge points per measure): eye examinations and hemoglobin A1c testing for patients with diabetes, chlam

276 -adhered to, whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mellitus coul

277 ease between 2006 and 2010, but increases in hemoglobin A1c testing may have contributed to rising di

278 cators: disease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein chol

279 cators: disease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein chol

280 , placed persons were more likely to receive hemoglobin A1C tests (RR = 1.10, 95% CI: 1.02, 1.19) and

281 glucose test (55% effectiveness; $498), or a hemoglobin A1c threshold of 5.5% (45% effectiveness; $76

282 Hemoglobin A1c thresholds of 5.7% and 6.5% were the leas

283 traits, including increased fasting glucose, hemoglobin A1C, total and LDL cholesterol, triglycerides

284 DM had higher mean (SD) preoperative BMI and hemoglobin A1C values (39.4 [8.5] and 8.7% [3.8%] of tot

285 Prediabetes was defined as follows: 1) hemoglobin A1c values ranging from 5.7% to 6.4% or 2) fa

286 Reductions in hemoglobin A1c values were similar across monotherapies

287 HDL-, blood pressure-, fasting glucose- and hemoglobin A1C values.

288 ss, self-efficacy, medication adherence, and hemoglobin A1c values.

289 29.7 (interquartile range 25.5-35.3), median hemoglobin A1c was 6.8 (interquartile range 6.2-7.8), an

290 in nondiabetic individuals, a 1% increase in hemoglobin A1c was associated with greater AD signature

291 At admission to ICU, hemoglobin A1c was measured in eligible patients.

292 Preoperative hemoglobin A1c was not significantly associated with mor

293 dds ratio, 0.27) than the control group, and hemoglobin A1c was on average 0.38% lower in the treatme

294 ts relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (co

295 d outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and hea

296 age, sex, hypertension, hyperlipidemia, and hemoglobin A1c were collected.

297 Reductions in fasting glucose levels and hemoglobin A1c were greater after distal gastric bypass.

298 measured IOP, CCT, FBS, fasting insulin, and hemoglobin A1c were null.

299 whereas total body fat mass, VAT, SSAT, and hemoglobin A1c were reduced comparably in both intervent

300 Associations of BP and hemoglobin A1c with change in eGFR were strongest for eG